References
Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P . Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006; 76: 23–32.
Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O’Keefe C et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113: 1315–1325.
Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009; 114: 3448–3458.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.
Petak I, Danam RP, Tillman DM, Vernes R, Howell SR, Berczi L et al. Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Diff 2003; 10: 211–217.
Jones CL, Wain EM, Chu CC, Tosi I, Foster R, McKenzie RC et al. Downregulation of Fas gene expression in Sezary syndrome is associated with promoter hypermethylation. J Invest Dermatol 2010; 130: 1116–1125.
Ghanim V, Herrmann H, Heller G, Peter B, Hadzijusufovic E, Blatt K et al. 5-azacitidine and decitabine exert proapoptotitc effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and syndergism with FAS-lignad. Blood 2012; 119: 4242–4252.
Claessens YE, Park S, Dubart-Kupperschmitt A, Mariot V, Garrido C, Chretien S et al. Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood 2005; 105: 4035–4042.
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419–425.
Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR . An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 2007; 449: 1073–1077.
Chim CS, Chan WW, Kwong YL . Epigenetic dysregulation of the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in acute leukaemias. J Clin Path 2008; 61: 844–847.
Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Testoni N et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci USA 2009; 106: 16811–16816.
Itzykson R, Thépot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117: 403–411.
Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28: 605–613.
Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009; 114: 2764–2773.
Acknowledgements
This work was supported by grants from the Direction régionale de la recherche clinique AP-HP (PHRC MAD-06). SE was recipient of a grant from the Canceropole Ile-de-France and from the Société Française d’Hématologie (SFH); CH and BB were recipients of a grant from Fondation pour la Recherche Médicale. We are undebted to Professor B Quesnel, Lille; Professor O Beyne-Rauzy, Toulouse; Professor M Hunault-Berger Angers, Dr S Park, Paris Cochin; Dr B Slama, Avignon; for recording patients.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author contributions
SE, CH and BB performed research; EA, VB, TC, CL, PM and FD analyzed data; HJ contributed analytical tools and analyzed data; ES and MF analyzed data and wrote the manuscript.
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Ettou, S., Audureau, E., Humbrecht, C. et al. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML. Leukemia 26, 2297–2299 (2012). https://doi.org/10.1038/leu.2012.152
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.152
- Springer Nature Limited
This article is cited by
-
Gene expression signatures associated with sensitivity to azacitidine in myelodysplastic syndromes
Scientific Reports (2020)
-
Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
BMC Hematology (2018)
-
Epigenetics of myelodysplastic syndromes
Leukemia (2014)
-
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
Leukemia (2014)
-
Epigenetic alterations in osteosarcoma: promising targets
Molecular Biology Reports (2014)